ABSTRACT:
For the measurement of tadalafil in tablet formulation, two straight forward, affordable, accurate, and exact UV and first derivative spectrophotometric techniques have been devised. Tadalafil exhibits zero crossover at 284nm in the first order derivative spectra (Method-B) and an absorbance peak at 284nm (Method-A). With these two techniques, Beer's law is followed in the concentration range of 20–120 micrograms/mL. The analysis's findings were statistically confirmed, and the recovery studies were deemed adequate. Their conclusions were unaffected by the prevalent excipients and additives.
Cite this article:
Mayur S. Jain, Shashikant D. Barhate. Estimation of Tadalafil in Tablet Dosage form by UV Spectrophotometric Method. Asian Journal of Pharmaceutical Research. 2025; 15(1):6-8. doi: 10.52711/2231-5691.2025.00002
Cite(Electronic):
Mayur S. Jain, Shashikant D. Barhate. Estimation of Tadalafil in Tablet Dosage form by UV Spectrophotometric Method. Asian Journal of Pharmaceutical Research. 2025; 15(1):6-8. doi: 10.52711/2231-5691.2025.00002 Available on: https://asianjpr.com/AbstractView.aspx?PID=2025-15-1-2
REFERENCES:
1. Pomerol J M and Rabasseda X. Drugs Today (Barc), 2003; 39: 103-113.
2. Gupta M, Kovar A and Meibohm B. J Clin Pharmacol. 2005; 45: 987-1003.
3. Corbin J D and Francis S H. Int J Clin Pract. 2002; 56: 453-459.
4. Ashak K Shakya, Ahmed N A Abu-Awwad, Tawfiq A Arafat and Munther melhim, J Chromatogr B. 2007; 852: 403-408.
5. Ramakrishna N V S, Vishwottam K N and Puran M. J Chromatogr B. 2004; 809: 243-249.
6. Natarajan R, Prabhu C, Rajendran NN. Formulation and evaluation of oral jelly containing tadalafil. Int J Res Pharm Chem. 2014; 4: 479-83.
7. Mohammad Yunoos, D Gowri Shankar, B Pragathi Kumar. The determination of tadalafil in the bulk and pharmaceutical dosage form. E-J Chem. 2010; 7: 833-6.
8. Zamirkhan, Amod SP, Atul AS. Estimation of tadalafil in bulk material and in pharmaceutical formulation by using derivative spectroscopy. Int J Spectrosc. 2014: 1-6. https://doi.org/10.1155/2014/392421